Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trial
Engineered Treg Donor Cell Therapy to Prevent Graft-Versus-Host Disease
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk B-cell Lymphoma Patients: Final Long-term Analysis From a Prospective Multicenter Phase-ii Trial
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for recurrent/metastatic cervical cancer after platinum failure: primary results from a phase 2 study
Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis: an open-label, phase 2 trial
Tamoxifen reduces mitochondrial respiration, oncogenic signaling and mutant allele burden in a myeloproliferative neoplasm subset
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron variants
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD